RHBDD1 induces cell cycle arrest in TP53-mutant NSCLC cells by promoting endoplasmic reticulum-associated degradation of p53 and DNA-PKcs.

IF 3.4 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Yun Chen, Yang Wang, Shuai Shen, Libin Zhang, Jun Liu, Xiangyun Yan, Hao Peng, Zheyuan Xu
{"title":"RHBDD1 induces cell cycle arrest in TP53-mutant NSCLC cells by promoting endoplasmic reticulum-associated degradation of p53 and DNA-PKcs.","authors":"Yun Chen, Yang Wang, Shuai Shen, Libin Zhang, Jun Liu, Xiangyun Yan, Hao Peng, Zheyuan Xu","doi":"10.1186/s40001-025-03116-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>RHBDD1 is a tumor-promoting protein that enhances endoplasmic reticulum-associated degradation (ERAD). This study aimed to explore its effects on non-small cell lung cancer (NSCLC) cells.</p><p><strong>Methods: </strong>The potential roles of RHBDD1 in NSCLC were predicted through bioinformatics analysis. The predicted regulation of p53/DNA-PKcs signaling by RHBDD1-associated ERAD was further validated in TP53 wild-type and mutant NSCLC cells.</p><p><strong>Results: </strong>Bioinformatics analysis revealed that in the RHBDD1-highly expressed NSCLC samples, cell cycle was significantly downregulated, protein processing in endoplasmic reticulum (ER) was significantly upregulated, and p53 signaling pathway was inhibited. TP53 and PRKDC were identified as hub genes. Inhibition of cell cycle and activation of protein processing in ER were specifically enriched in TP53-mutant, RHBDD1-highly expressing samples, but not in TP53 wild-type ones. The protein levels of p53 and DNA-PKcs (encoded by the PRKDC gene) were more significantly altered by the DNA-PKcs inhibitor STL127705 and sh-RHBDD1 in NCI-H596 cells compared to A549 cells. In NCI-H596 cells transfected with pcDNA-RHBDD1, the reduced levels of DNA-PKcs and p53 were restored by co-treatment with p53 activators HBX41108 or Nutlin-3a. Cell cycle progression in NCI-H596 cells was significantly arrested at the S phase in both sh-RHBDD1 and pcDNA-RHBDD1 transfected groups. Both interventions led to decreased cell viability, which was reversed by co-treatment with the DNA-PKcs inhibitor STL127705 and further enhanced by Nutlin-3a. Increased levels of DNA-PKcs and p53, along with a modest reduction in ER stress markers, were observed in the sh-RHBDD1 group, whereas opposite trends were seen in the pcDNA-RHBDD1 group. Apoptosis was obviously inhibited in pcDNA-RHBDD1 transfected NCI-H596 cells, but not in transfected A549 cells. Co-localization of p53 with RHBDD1 and DNA-PKcs was prominently observed in TP53-mutant NSCLC cells, but not in wild-type cells.</p><p><strong>Conclusion: </strong>RHBDD1 arrests the cell cycle in TP53-mutant NSCLC cells through ERAD-dependent downregulation of p53 and DNA-PKcs. However, cell survival may be enhanced due to the inhibition of DNA-PKcs-regulated apoptosis.</p>","PeriodicalId":11949,"journal":{"name":"European Journal of Medical Research","volume":"30 1","pages":"859"},"PeriodicalIF":3.4000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12465477/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40001-025-03116-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: RHBDD1 is a tumor-promoting protein that enhances endoplasmic reticulum-associated degradation (ERAD). This study aimed to explore its effects on non-small cell lung cancer (NSCLC) cells.

Methods: The potential roles of RHBDD1 in NSCLC were predicted through bioinformatics analysis. The predicted regulation of p53/DNA-PKcs signaling by RHBDD1-associated ERAD was further validated in TP53 wild-type and mutant NSCLC cells.

Results: Bioinformatics analysis revealed that in the RHBDD1-highly expressed NSCLC samples, cell cycle was significantly downregulated, protein processing in endoplasmic reticulum (ER) was significantly upregulated, and p53 signaling pathway was inhibited. TP53 and PRKDC were identified as hub genes. Inhibition of cell cycle and activation of protein processing in ER were specifically enriched in TP53-mutant, RHBDD1-highly expressing samples, but not in TP53 wild-type ones. The protein levels of p53 and DNA-PKcs (encoded by the PRKDC gene) were more significantly altered by the DNA-PKcs inhibitor STL127705 and sh-RHBDD1 in NCI-H596 cells compared to A549 cells. In NCI-H596 cells transfected with pcDNA-RHBDD1, the reduced levels of DNA-PKcs and p53 were restored by co-treatment with p53 activators HBX41108 or Nutlin-3a. Cell cycle progression in NCI-H596 cells was significantly arrested at the S phase in both sh-RHBDD1 and pcDNA-RHBDD1 transfected groups. Both interventions led to decreased cell viability, which was reversed by co-treatment with the DNA-PKcs inhibitor STL127705 and further enhanced by Nutlin-3a. Increased levels of DNA-PKcs and p53, along with a modest reduction in ER stress markers, were observed in the sh-RHBDD1 group, whereas opposite trends were seen in the pcDNA-RHBDD1 group. Apoptosis was obviously inhibited in pcDNA-RHBDD1 transfected NCI-H596 cells, but not in transfected A549 cells. Co-localization of p53 with RHBDD1 and DNA-PKcs was prominently observed in TP53-mutant NSCLC cells, but not in wild-type cells.

Conclusion: RHBDD1 arrests the cell cycle in TP53-mutant NSCLC cells through ERAD-dependent downregulation of p53 and DNA-PKcs. However, cell survival may be enhanced due to the inhibition of DNA-PKcs-regulated apoptosis.

RHBDD1通过促进内质网相关的p53和DNA-PKcs降解,诱导p53突变的非小细胞肺癌细胞周期阻滞。
背景:RHBDD1是一种促进肿瘤的蛋白,可增强内质网相关降解(ERAD)。本研究旨在探讨其对非小细胞肺癌(NSCLC)细胞的影响。方法:通过生物信息学分析预测RHBDD1在非小细胞肺癌中的潜在作用。在TP53野生型和突变型NSCLC细胞中进一步验证了rhbdd1相关ERAD对p53/DNA-PKcs信号传导的预测调节。结果:生物信息学分析显示,在rhbdd1高表达的NSCLC样本中,细胞周期明显下调,内质网(ER)蛋白加工明显上调,p53信号通路受到抑制。中心基因为TP53和PRKDC。在TP53突变体和rhbdd1高表达的样本中,细胞周期的抑制和内质膜蛋白加工的激活特异性增强,而在TP53野生型样本中则不明显。与A549细胞相比,NCI-H596细胞中p53和DNA-PKcs(由PRKDC基因编码)的蛋白水平被DNA-PKcs抑制剂STL127705和sh-RHBDD1显著改变。在转染pcDNA-RHBDD1的NCI-H596细胞中,与p53激活剂HBX41108或Nutlin-3a共同处理后,DNA-PKcs和p53水平降低。sh-RHBDD1和pcDNA-RHBDD1转染组NCI-H596细胞的细胞周期进展均在S期被显著阻滞。两种干预都导致细胞活力下降,通过与DNA-PKcs抑制剂STL127705共同处理可以逆转这一趋势,并通过Nutlin-3a进一步增强。在sh-RHBDD1组中观察到DNA-PKcs和p53水平的增加,以及内质网应激标志物的适度减少,而在pcDNA-RHBDD1组中观察到相反的趋势。转染pcDNA-RHBDD1的NCI-H596细胞的细胞凋亡明显受到抑制,而转染A549细胞的细胞凋亡无明显抑制。p53与RHBDD1和DNA-PKcs的共定位在p53突变的非小细胞肺癌细胞中被显著观察到,而在野生型细胞中没有。结论:RHBDD1通过erd依赖性下调p53和DNA-PKcs抑制tp53突变的非小细胞肺癌细胞周期。然而,细胞存活可能由于抑制dna - pkcs调控的凋亡而增强。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
European Journal of Medical Research
European Journal of Medical Research 医学-医学:研究与实验
CiteScore
3.20
自引率
0.00%
发文量
247
审稿时长
>12 weeks
期刊介绍: European Journal of Medical Research publishes translational and clinical research of international interest across all medical disciplines, enabling clinicians and other researchers to learn about developments and innovations within these disciplines and across the boundaries between disciplines. The journal publishes high quality research and reviews and aims to ensure that the results of all well-conducted research are published, regardless of their outcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信